DekaBank Deutsche Girozentrale bought a new stake in QuidelOrtho Co. (NASDAQ:QDEL – Get Rating) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 1,838 shares of the company’s stock, valued at approximately $210,000.
Several other large investors have also made changes to their positions in QDEL. Western Pacific Wealth Management LP acquired a new position in QuidelOrtho in the fourth quarter valued at about $26,000. New Century Advisors LLC bought a new position in shares of QuidelOrtho in the fourth quarter valued at approximately $31,000. Exane Derivatives boosted its holdings in shares of QuidelOrtho by 4,883.3% in the 1st quarter. Exane Derivatives now owns 299 shares of the company’s stock worth $34,000 after acquiring an additional 293 shares in the last quarter. Emerald Advisers LLC bought a new stake in QuidelOrtho during the 4th quarter worth approximately $40,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in QuidelOrtho in the 4th quarter valued at $66,000. Institutional investors own 92.89% of the company’s stock.
QuidelOrtho Stock Performance
Shares of QuidelOrtho stock opened at $103.26 on Monday. QuidelOrtho Co. has a 52 week low of $88.05 and a 52 week high of $180.06. The stock has a market capitalization of $4.32 billion, a price-to-earnings ratio of 4.36 and a beta of 0.04. The firm has a fifty day moving average of $99.72 and a two-hundred day moving average of $103.49.
QuidelOrtho (NASDAQ:QDEL – Get Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported $11.53 EPS for the quarter, beating analysts’ consensus estimates of $9.17 by $2.36. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $865.05 million. QuidelOrtho had a return on equity of 56.46% and a net margin of 43.26%. QuidelOrtho’s revenue was up 167.0% on a year-over-year basis. During the same period in the prior year, the business posted $4.27 EPS. As a group, research analysts forecast that QuidelOrtho Co. will post 14.92 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the company. UBS Group initiated coverage on QuidelOrtho in a research note on Wednesday, July 20th. They issued a “sell” rating and a $86.00 target price for the company. JPMorgan Chase & Co. started coverage on QuidelOrtho in a research report on Friday, June 17th. They issued a “neutral” rating on the stock. Finally, StockNews.com raised QuidelOrtho from a “hold” rating to a “buy” rating in a research note on Friday, May 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.67.
QuidelOrtho Company Profile
QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company’s product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products.
Receive News & Ratings for QuidelOrtho Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for QuidelOrtho and related companies with MarketBeat.com’s FREE daily email newsletter.